IDEAS home Printed from https://ideas.repec.org/a/spr/aphecp/v16y2018i5d10.1007_s40258-018-0408-4.html
   My bibliography  Save this article

Costs in the Treatment of Schizophrenia in Adults Receiving Atypical Antipsychotics: An 11-Year Cohort in Brazil

Author

Listed:
  • Wallace Breno Barbosa

    (Federal University of Minas Gerais
    Federal University of Minas Gerais)

  • Juliana de Oliveira Costa

    (Federal University of Minas Gerais
    Federal University of Minas Gerais)

  • Lívia Lovato Pires Lemos

    (Federal University of Minas Gerais
    Federal University of Minas Gerais)

  • Rosângela Maria Gomes

    (Federal University of Minas Gerais
    Federal University of Minas Gerais)

  • Helian Nunes Oliveira

    (Federal University of Minas Gerais)

  • Cristina Mariano Ruas

    (Federal University of Minas Gerais)

  • Francisco de Assis Acurcio

    (Federal University of Minas Gerais
    Federal University of Minas Gerais)

  • Corrado Barbui

    (University of Verona)

  • Marion Bennie

    (Strathclyde University)

  • Brian Godman

    (Strathclyde University
    Liverpool University Management School
    Karolinska University Hospital Huddinge
    Sefako Makgatho Health Sciences University)

  • Augusto Afonso Guerra

    (Federal University of Minas Gerais
    Federal University of Minas Gerais)

Abstract

Background Schizophrenia is associated with significant economic burden. In Brazil, antipsychotic drugs and outpatient and hospital services are provided by the Brazilian National Health System (SUS) for patients with schizophrenia. However, few studies capture the cost of managing these patients within the Brazilian NHS. This is important to appraise different management approaches within universal healthcare systems. Objective Our objective was to use real-world data to describe the costs associated with the treatment of schizophrenia in adults receiving atypical antipsychotics in Brazil from 2000 to 2010. Methods We integrated three national databases for adult patients with schizophrenia receiving one or more atypical antipsychotics. We assessed only direct medical costs and the study was conducted from a public-payer perspective. A multivariate log-linear regression model was performed to evaluate associations between costs and clinical and demographic variables. Results We identified 174,310 patients with schizophrenia, with mean ± standard deviation (SD) annual costs of $US1811.92 ± 284.39 per patient. Atypical antipsychotics accounted for 79.7% of total costs, with a mean annual cost per patient of $US1578.74 ± 240.40. Mean annual costs per patient were $US2482.90 ± 302.92 for psychiatric hospitalization and $US862.96 ± 160.18 for outpatient psychiatric care. Olanzapine was used by 47.7% of patients and represented 62.8% of the total costs of atypical antipsychotics. Patients who used clozapine had the highest mean annual cost per patient for outpatient psychiatric care and psychiatric hospitalization. Conclusions Atypical antipsychotics were responsible for the majority of the schizophrenia treatment costs, and psychiatric hospitalization costs were the highest mean annual cost per patient. Authorities should ensure efficient use of atypical antipsychotics and encourage outpatient psychiatric care over psychiatric hospitalization where possible.

Suggested Citation

  • Wallace Breno Barbosa & Juliana de Oliveira Costa & Lívia Lovato Pires Lemos & Rosângela Maria Gomes & Helian Nunes Oliveira & Cristina Mariano Ruas & Francisco de Assis Acurcio & Corrado Barbui & Mar, 2018. "Costs in the Treatment of Schizophrenia in Adults Receiving Atypical Antipsychotics: An 11-Year Cohort in Brazil," Applied Health Economics and Health Policy, Springer, vol. 16(5), pages 697-709, October.
  • Handle: RePEc:spr:aphecp:v:16:y:2018:i:5:d:10.1007_s40258-018-0408-4
    DOI: 10.1007/s40258-018-0408-4
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40258-018-0408-4
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.

    File URL: https://libkey.io/10.1007/s40258-018-0408-4?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:aphecp:v:16:y:2018:i:5:d:10.1007_s40258-018-0408-4. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.